Stichting Health Action International

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 13 Mar 2024
How to read and use this data card.
Download this datacard

Overview

Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

2.75 Fte (5)

Lobbyists with EP accreditation

0

High-level Commission meetings

5

Lobbying Costs over the years

  • Info

    Stichting Health Action International   (HAI)

    EU Transparency Register

    44361352681-84 First registered on 30 Nov 2009

    Goals / Remit

    Health Action International is a non-profit, independent global network of consumer groups, public interest NGOs, healthcare professionals, academics, and individuals working and interested on pharmaceutical policy issues. HAI’s mission is to increase equitable access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.

    In Europe, HAI has grown to become a pre-eminent voice in medicines policy intervention/discussion, supported by a strong European network of 125 individual and organization members from 19 European Union (EU) Member States and 14 other non-EU countries. The HAI Europe projects team, based in Amsterdam, is responsible for coordinating the work programmed and related activities within the European region. HAI monitors and advocates on EU policies that affect medicines on three key thematic priorities: Access to Needed Medicines, the Rational Use of Medicines, and the Democratization of Medicines Policy.

    Main EU files targeted

    HAI advocates for policy initiatives that help to address current shortfalls/shortcomings in access to medicines. In Europe, HAI monitors EU policy initiatives and developments that have an impact on access to medicines, their rational use and on the democratization of medicines policy. We also work on exposing major risks that the use of Artificial Intelligence (AI) in health can cause, including discrimination, harming citizens health and safety, and the exacerbation of health inequalities, which infringes on patients’ fundamental rights. Where needed, we issue recommendations for improvement on specific topics. EU legislation, policies and initiatives of particular interest include: implementation of proposals on EU cooperation on Health Technology Assessment and clinical trials regulation; discussion of European Pharmaceutical Strategy and review of EU pharmaceutical legislation, orphan designation and other IP incentives; European Union IP Action Plan and enforcement strategy, including revision of Supplementary Protection Certificate Regulation; Competition policy; EU trade agreements with impact on access to medicines; Innovative Medicines Initiative and Horizon Europe; Multiannual Financial Framework (MFF); implementation of the One Health Action Plan against AMR; European Medicine Agency (EMA)'s policies and activities; tackling medicines shortages.

    Address

    Head Office
    Overtoom, 60/II
    Amsterdam 1054HK
    NETHERLANDS
    EU Office
    Overtoom, 60/II
    Amsterdam 1054HK
    NETHERLANDS

    Website

  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    100%1
    75%1
    50%1
    25%2

    Lobbyists (Full time equivalent)

    2.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 24 Apr 2024

    Name Start date End Date
    Ms Hannah VAN KOLFSCHOOTEN 14 Dec 2022 14 Dec 2023
    Ms Janneke VAN OIRSCHOT 09 Dec 2022 09 Dec 2023
    Mr Jaume VIDAL 04 Nov 2022 04 Nov 2023
    Ms Ellie WHITE 27 Oct 2021 11 Feb 2022
    Mr Jaume VIDAL 27 Oct 2021 27 Oct 2022
    Mr Jaume VIDAL 19 Sep 2019 19 Sep 2020
    Ms Ellie WHITE 14 Sep 2019 12 Sep 2020
    Ms Ancel·la Santos Quintano 13 Oct 2018 25 Apr 2019
    Mr Jaume VIDAL 13 Oct 2018 19 Sep 2019
    Ms Ancel·la Santos Quintano 14 Oct 2017 13 Oct 2018
    Mr Jaume VIDAL 20 Jul 2017 07 Jul 2018
    Ms Tessel Mellema 07 Sep 2016 21 Jul 2017
    Ms Ancel·la Santos Quintano 07 Sep 2016 07 Sep 2017
    Ms Tessel Mellema 27 Aug 2015 26 Aug 2016
    Ms Ancel·la Santos Quintano 27 Aug 2015 26 Aug 2016
    Ms Aliénor Devalière 27 Aug 2015 23 Jun 2016
    Ms Ancel·la Santos Quintano 01 May 2014 05 Jun 2015
    Ms Aliénor Devalière 07 Jun 2014 05 Jun 2015
    Mrs Aliénor Devalière 07 Jun 2014 27 Jan 2015
    Ms Tessel Mellema 01 May 2014 05 Jun 2015
    Mrs Ancel·la Santos Quintano 01 May 2014 27 Jan 2015
    Ms Tessel Mellema 25 Jun 2013 01 May 2014
    Mrs Ancel·la Santos Quintano 30 May 2013 01 May 2014
    Ms Katrina Perehudoff 22 Sep 2012 17 Jun 2013
    Ms Tessel Mellema 20 Sep 2012 25 Jun 2013

    Complementary Information

    HAI has one full-time policy advisor that is solely focused on our EU projects. He is supported by Admin, Communications, PME & our Executive Director.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    HAI is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins (ISDB), the Transatlantic Consumer Dialogue (TACD), the Medicines in Europe Forum (MiEF), the European Alliance for Responsible R&D and Affordable Medicines, the Antimicrobial Resistance Coalition (ARC), and Global Snakebite Initiative. At the national level HAI is member of the Dutch Global Health Alliance (DGHA) and the Medicijnen Netwerk. In addition, HAI enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required.

    HAI is in official relations with the WHO and collaborates with the organization on several projects as well as attending governing bodies and ad-hoc meetings.

    Others:
    EU Pharmaceutical Strategy
    IP Package
    Framework Program 10
    HERA work plan
    EU guidelines and National Action Plans of Member States on Anti-Microbial Resistance
    European Health- Data Space and the EMA / HMA Big Data Workplan
    The EU Artificial Intelligence Act
    The EU AI Liability Directives
    The EU Medical Devices Regulation
    European Health Data Space
    GDPR

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year

    1,152,808€

    Major funding types in closed year

    Grants, Public financing, EU funding, Member's contribution

    Major contributions in closed year

    TypeNameAmount
    Contribution Dutch Ministry of Foreign Affairs 22,958€
    Contribution Embassy of the Kingdom of the Netherlands in Burundi 115,440€
    Contribution Perl's Foundation 77,904€
    Contribution European Artificial Intelligence Fund 84,264€
    Contribution Helmsley Charitable Trust 973,639€
    Contribution Hennecke Foundation 100,483€
    Contribution IDA Charity Foundation 92,500€
    Contribution Lillian Lincoln Foundation 148,849€
    Contribution Open Society Foundation 82,394€
    Contribution UNITAID 170,114€
    Contribution The Waterloo Foundation 57,480€
    Contribution European Commission 731,854€
    Contribution Embassy of the Kingdowm of the Netherlands in Burundi 419,954€
    Grant European Commission 731,854€

    Other financial info

    N/A

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    Artificial intelligence and digital

    Communication activities

    For our publications please visit: https://haiweb.org/publication/
    For our press releases and other news please visit: https://haiweb.org/news/

    In 2023, we published 12 reports, briefings and consultation responses and hosted a number of events and meetings to discuss and disseminate these. These publications formed the basis of our advocacy work. In the same period, our European project work and staff and members were quoted or mentioned in the media at least 42 times, demonstrating the added value of our published materials and that our staff are seen by media contacts as experts in their field. The European Projects Team has worked closely with the HAI Communications Team to develop engaging content that promoted our work and helped achieve project objectives. We continued the development of the TRIPS Flexibilities Navigator to improve its useability and reach. This living resource designed to help to educate lawmakers, policymakers, researchers, and the public about how the use of TRIPS Flexibilities as a legitimate tool to improve access to patented medicines has received excellent feedback from users.

    Other activities

    HAI is a member of the European Medicines Agency Patients' and Consumers' Working Party (PCWP); and a member of the HTA Network Stakeholder Pool.

  • Meetings

    Meetings

    5 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard